Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Down 5.41%
As of Friday, October 16, Arcturus Therapeutics Holdings Inc.’s ARCT share price has dipped by 5.41%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. ARCT
$10.34
-0.93
-8.25%
October 16, 2026 4:00:00 PM
EST
Volume: 831,612
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Commentary & Analysis
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Down 5.32%
As of Wednesday, October 14, Arcturus Therapeutics Holdings Inc.’s ARCT share price has dipped by 5.32%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Down 5.08%
As of Tuesday, October 13, Arcturus Therapeutics Holdings Inc.’s ARCT share price has dipped by 5.08%, which has investors questioning if this is right time to buy.Michael Rose
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Down 6.48%
As of Monday, October 12, Arcturus Therapeutics Holdings Inc.’s ARCT share price has dipped by 6.48%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Up 6.53%
As of Friday, October 09, Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 6.53%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $293.9 | $208.8 | 32% |
|
| Shares Out (Mil) | 28.4 | 53.9 | 36% |
|
| Institutional Ownership | 90.4% | 93.1% | 58% |
|
| Float (Mil) | 26.2 | 41.4 | 33% |
|
| Beta | 2.27 | 0.95 | 94% |
|
| Avg Daily Volume (000s) | 687 | 614 | 63% |
|
| Price Change (52-week) |
(52.1%) | 45.3% | 19% |
|
| Growth | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 53.9% | 12.8% | 96% |
|
| Net Income (5yr) | 1.8% | (10.2%) | 42% |
|
| EPS (5yr) | 7.5% | 15.7% | 43 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.2%) | (15.7%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($0.680) | ($3.455) | ($3.703) | |
| Month Ago EPS | ($0.670) | ($3.419) | ($3.613) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.878) | ($3.858) | ($4.024) | |
| Year/Year Chg | (18.8%) | 43.8% | 53.1% | |
| Financials | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $29 | $37 | 16% |
|
| Net Income (TTM) (Mil) | ($93) | ($44) | 12% |
|
| EPS (TTM) | ($3.327) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($73) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($60) | $2 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $19 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $42 | $174 | 15% |
|
| Valuation | ARCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.71 | 2.09 | 48% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (195.5%) | 66.0% | 1% |
|
| Net Margin | (317.6%) | (75.3%) | 3% |
|
| ROA | (35.0%) | (47.2%) | 15% |
|
| ROE | (46.3%) | (54.2%) | 16% |
|
| Liabilities to Assets | 23.4% | 29.1% | 16% |
|
| F-Score | 1 | 2 | 1% |
|
Arcturus Therapeutics Holdings Inc. did not pass any screens on 10/16/2026.
